We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol-Myers Squibb Company (BMY - Free Report) announced long-term pooled efficacy and safety results from the phase III CheckMate-017 and CheckMate-057 studies in patients with previously-treated, advanced non-small cell lung cancer (NSCLC).
Shares of the company have lost 3.2% in the year so far against the industry’s growth of 1.9%.
At five years, patients treated with Opdivo (nivolumab) continuedto experience long-term overall survival (OS) benefit versus docetaxel. Treatment with Opdivo was associated with a 5-year OS rate of 13.4% compared with 2.6% with docetaxel in previously-treated NSCLC patients.
The OS benefit with the drug was observed across all patient subgroups, including those with PD-L1 expression on <1% of tumor cells. Further, the safety profile for Opdivo was consistent with prior findings in the second-line setting, and no new safety signals were observed with the longer follow-up. Only two of the 70 patients currently on study experienced a new treatment-related select adverse event (AE) between years 3 and 4. There were no new treatment-related select AEs reported between years 4 and 5 among the 55 patients still on study.
This pooled analysis represents the longest follow-up of previously-treated NSCLC patients treated with Immuno-Oncology therapy in phase III randomized studies.
Opdivo is Bristol-Myers’ primary growth driver. It is currently approved in the United States, the EU, Japan and other countries for several cancer indications. The company is working on expanding the label of the drug further.
Nevertheless, competition is stiff in the NSCLC market. Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda, commands a strong place in the first-line NSCLC market. Other PD-L1 inhibitors available in the market are AstraZeneca’s (AZN - Free Report) Imfinzi and Roche’s (RHHBY - Free Report) Tecentriq.
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Bristol-Myers' (BMY) Opdivo Shows Long-Term Survival Benefit
Bristol-Myers Squibb Company (BMY - Free Report) announced long-term pooled efficacy and safety results from the phase III CheckMate-017 and CheckMate-057 studies in patients with previously-treated, advanced non-small cell lung cancer (NSCLC).
Shares of the company have lost 3.2% in the year so far against the industry’s growth of 1.9%.
At five years, patients treated with Opdivo (nivolumab) continuedto experience long-term overall survival (OS) benefit versus docetaxel. Treatment with Opdivo was associated with a 5-year OS rate of 13.4% compared with 2.6% with docetaxel in previously-treated NSCLC patients.
The OS benefit with the drug was observed across all patient subgroups, including those with PD-L1 expression on <1% of tumor cells. Further, the safety profile for Opdivo was consistent with prior findings in the second-line setting, and no new safety signals were observed with the longer follow-up. Only two of the 70 patients currently on study experienced a new treatment-related select adverse event (AE) between years 3 and 4. There were no new treatment-related select AEs reported between years 4 and 5 among the 55 patients still on study.
This pooled analysis represents the longest follow-up of previously-treated NSCLC patients treated with Immuno-Oncology therapy in phase III randomized studies.
Opdivo is Bristol-Myers’ primary growth driver. It is currently approved in the United States, the EU, Japan and other countries for several cancer indications. The company is working on expanding the label of the drug further.
Nevertheless, competition is stiff in the NSCLC market. Merck’s (MRK - Free Report) PD-L1 inhibitor, Keytruda, commands a strong place in the first-line NSCLC market. Other PD-L1 inhibitors available in the market are AstraZeneca’s (AZN - Free Report) Imfinzi and Roche’s (RHHBY - Free Report) Tecentriq.
Bristol-Myers currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bristol-Myers Squibb Company Price
Bristol-Myers Squibb Company price | Bristol-Myers Squibb Company Quote
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana. Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>